Semin Arthritis Rheu: The efficacy and safety of cyromos in the treatment of systemic lupus.

!---- New evidence suggests that mTOR as a target has a potential therapeutic effect on SLE.but most studies are observational studies or case reports with limited sample sizes.study assessed the efficacy and safety of SLE by siromos through systematic evaluation and meta-analysis.researchers systematically searched Medline/PubMed, EMBASE, Cochrane and Scopus.include sleight of office in original case reports, case series, observational studies, and clinical trials that report seromos on sLE patient outcomes or safety data., if possible, a random effect meta-analysis is performed to calculate the aggregate effect. A total of nine studies were identified, including 145 patients.exposure time to siromos was 245.8 patients - years- and most studies used a dose of 1-3 mg/day.111 clinical patients, the combined reduction of SLEDAI, BILAG and Pernison was 4.85 (95% CI 3.44-6.25), 1.98 (95% CI 0.23-3.74) and 13.17 mg/day (95% CI 0.71-25.63), respectively. of the 23 active SLE patients who started using siromos in, 17 (73.9%) were remissioned.in 22 patients with inactive lupus nephritis, 21 (95.5%) continued to repath.blood, mucous skin and blood lipid abnormalities are the most common adverse events.reported that 9.28 percent of patients (13/140) stopped early due to side effects, most of which were mild and recovered quickly after discontinuation.summary of available data shows that siromos treatment sLE is promising and well tolerated.the need for further randomized controlled trials to assess the potential benefits and risks of seromos treatment for SLE..